Insulin regulates metabolism by
creating the pancreas that allows your body to use glucose from carbohydrates
in the food. Insulin helps to keep your blood sugar level from getting
too high or too low. Insulin enables the entry of glucose in the cell and
maintains level of blood glucose. In diabetes treatment, patient need insulin
injections to allow body to process sugar and avoid complications from
hyperglycemia
Rising ubiquity of diabetes is one
of the important factors bolstering the growth of the CIS insulin market. The
increasing pervasiveness of obesity disorder is expected to be imperative for
this industry. The prominent circumstances that might occur owing to this
disorder include type II diabetes, obesity and hypertension. The government
supports and rising R&D in insulin product is projected to exhibit lucrative
growth in this industry. The report also analyzes several driving and
restraining factors and their impact on the market during the forecast period.
The report provides a detailed view
of the CIS insulin market based on products, application and region.
Based on products, CIS insulin market is further bifurcated into long
acting, short acting, rapid acting, premixed and intermediate acting.
Long acting insulin accounted for a very large chunk of the global CIS
insulin market. Rapid acting is another leading project and expected to exhibit
strong growth over the forecast period. The CIS insulin market is further
classified based on source into analogs and human recombinant. The analog
segment holds largest share of the CIS insulin market. Key applications
of insulin include type I and other diabetes and type II diabetes. Type II
diabetes dominated CIS insulin market and accounted for significant share of
total market.
Regional segmentation includes the
current and forecast demand of CIS insulin in North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa with its further
bifurcation into major countries including U.S. Germany, France, UK, China, Japan,
India and Brazil. The CIS insulin market is dominated by North America followed
by Europe. Asia Pacific is expected to witness significant growth over the
forecast period.
The report covers detailed
competitive scenario including the company overviews, financial revenues of the
key participants to develop their positions in the global market. Major market
players include Merck & Co. Inc., Novo Nordisk, Eli Lilly and Company,
Oramed Pharmaceuticals, Nanjing Xinbai Pharmaceutical Co. Ltd., Sanofi Aventis,
Boehringer Ingelheim, Farmak and Biocon.
This report segments the global CIS
insulin market as follows:
CIS Insulin Market: Product Segment
Analysis
- Long Acting
- Short Acting
- Rapid Acting
- Premixed
- Intermediate Acting
CIS Insulin Market: Source Segment
Analysis
- Analogs
- Human Recombinant
CIS Insulin Market: Application
Segment Analysis
- Type I Diabetes
- Type II Diabetes
CIS Insulin Market: Regional Segment
Analysis
- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East & Africa
Contact
US
3422 SW 15 Street,
Suit #8138,
Deerfield Beach,Florida 33442,
USATel: +1-386-310-3803GMT FREE
Deerfield Beach,Florida 33442,
USATel: +1-386-310-3803GMT FREE
Tel: +49-322
210 92714
USA/Canada Toll Free No. 1-855-465-4651 FREE
USA/Canada Toll Free No. 1-855-465-4651 FREE
No comments:
Post a Comment